Merck released phase III data for an injection form of its blockbuster cancer treatment drug Keytruda and announced the FDA is reviewing the application for approval. The data sho ...

A bitter management shake-up. Angry public outbursts. A “narcissistic” pastor whose word is gospel. What in God’s name is ...

Intel, Core BTS, Salesforce, Verizon, ServiceNow, Cisco and Cyderes were among the tech companies making key executive hires ...

AstraZenca is testing a once-daily PCSK9 inhibitor, currently known as AZD0780. After 12 weeks of use alongside standard ...

Guggenheim analyst Vamil Divan maintained a Buy rating on Merck & Company (MRK – Research Report) today and set a price target of ...

A class action lawsuit was filed against Merck & Co. (MRK) by Levi & Korsinsky on February 12, 2025. The plaintiffs ...

The stock's rise snapped a three-day losing streak.

Merck & Co. Inc. closed 41.19% below its 52-week high of $134.63, which the company reached on June 25th.

Merck & Co has a lower P/E than the aggregate P/E of 26.97 of the Pharmaceuticals industry. Ideally, one might believe that ...

a senior vice president in Merck's oncology division, said in an interview. The company expects peak adoption of the drug to be at least 30% to 40% of patients on Keytruda, she added. "We expect ...